NextGen Ventures

Senior Associate responsible for sourcing, evaluating, and executing investments and supporting portfolio companies. Previously an M&A professional at Cordance and analyst at Software Equity Group.

Investment manager at Noaber.

Thijs Schaap is an impact investor at Noaber, where he focuses on companies that use technology to improve healthcare in the Netherlands and Europe while generating both financial returns and positive social impact. He previously worked at a public investment fund, which prepared him for healthtech investing. He works with entrepreneurs domestically and abroad to help develop their ventures.

Cofounder, CTO, and board member at AbCellera who co-invented the high-throughput microfluidic platform central to its antibody discovery. She previously served as COO from 2019 to 2025 and holds a PhD from the University of British Columbia.

Harm-Jan Wessels is co-founder and investor at Coforix, with 30 years of experience in the healthcare and software industries. He previously founded international businesses that were acquired by General Electric (Applicare) and Philips (Forcare), with domain expertise in digital imaging, electronic medical records, and artificial intelligence. He also works as an investor and board member.

Peter Haasjes studied business administration and worked for several years at a commercial investment fund before moving into healthtech investing. At Noaber he served as an investment manager and later as director of Nextgen Ventures, and since 2023 he has also been responsible for Noaber's investment activities, working within an impact investing approach.

Rudy Mareel is a Non-Executive Director at InnoCore Pharmaceuticals and serves on the boards of several other healthcare-related companies. His background spans strategic planning, operational management, and change leadership in senior healthcare roles, with experience across medical nutrition, medical and pharmaceutical distribution, in vivo and in vitro diagnostics, medical technology, and generic and biosimilar drug development and marketing. He also has experience in governance and sustainability.

Paul van Ooik works at Noaber, where he evaluates health-focused companies for both their profitability and their potential to improve healthcare for patients and professionals. He previously worked at VitalHealth, where he gained experience with Noaber's early-stage investments, and at Philips in the M&A team with a focus on medical technology.